FDA Clearance Tracker · P130008-S089
Inspire Upper Airway Stimulation
Last checked: Nov 20, 2026Latest source record: Mar 20, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 20, 2023
Approved
Time to decision
213 days
Received Aug 19, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P130008-S089
- Device name
- Inspire Upper Airway Stimulation
- Applicant
- Inspire Medical Systems
- Applicant location
- Maple Grove, MN
- Received
- Aug 19, 2022
- Decided
- Mar 20, 2023
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130008
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Inspire Upper Airway Stimulation (UAS) the device is used to treat a subset of pediatric Down syndrome patients between the age of 13-18 with severe OSA (apnea-hypopnea index [AHI] of greater than or equal to 10 and less than or equal to 50) who: 1) Do not have complete concentric collapse at the soft palate level;2) Are contraindicated for or not effectively treated by adenotonsillectomy; 3) Have been confirmed to fail, or cannot tolerate positive airway pressure (PAP) therapy despite attempts to improve compliance; and4) Have followed standard of care in considering all other alternative/adjunct therapies. PAP failure is defined as an inability to eliminate OSA, and PAP intolerance is defined as: a. Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or b. Unwillingness to use PAP (for example, a patient returns the PAP system after attempting to use it).
Source documents
Other decisions for Inspire Medical Systems
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Inspire Upper Airway Stimulation SystemPMA supplement
P130008-S090 · Decided Jun 8, 2023 · 234 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.